GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

pivekimab sunirine   Click here for help

GtoPdb Ligand ID: 14543

Synonyms: Decnupaz® | IMGN 632 | IMGN-632 | IMGN632 | pivekimab sunirine-pvzy | PVEK [2]
Approved drug
pivekimab sunirine is an approved drug
Compound class: Antibody
Comment: Pivekimab sunirine (IMGN632) is an interleukin 3 receptor subunit alpha (IL3RA) antibody-drug conjugate [2,4]. The payload is a DNA mono-alkylating compound (a monoamine indolinobenzodiazepine pseudodimer) [1]. The antibody is intended to deliver the toxic conjugate to neoplastic blood cells that overexpress IL3RA [5-6].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Archer KE, Reid EE, Shizuka M, Woods J, Harris L, Maloney EK, Bartle LM, Ab O, Wilhelm A, Setiady Y et al.. (2019)
Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs).
ACS Med Chem Lett, 10 (8): 1211-1215. [PMID:31413807]
2. Cole FM, Laszlo GS, Lunn-Halbert MC, Kehret AR, Zweidler-McKay PA, Rodríguez-Arbolí E, Wu D, Nyberg K, Li J, Lim SYT et al.. (2025)
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).
Leukemia, 39 (5): 1243-1246. [PMID:40119158]
3. Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Todisco E, Sweet KL, Pemmaraju N, Lane AA, Torres-Miñana L et al.. (2024)
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Lancet Oncol, 25 (3): 388-399. [PMID:38423051]
4. Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, Bai C, Rui L, Laleau R, Liu F et al.. (2018)
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
Blood Adv, 2 (8): 848-858. [PMID:29661755]
5. Pelosi E, Castelli G, Testa U. (2023)
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm.
Int J Mol Sci, 24 (3). [PMID:36769040]
6. Zanotta S, Galati D, De Filippi R, Pinto A. (2024)
Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
Int J Mol Sci, 25 (3). [PMID:38338733]